Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Canada House Wellness Group Inc stock logo
CHV
Canada House Wellness Group
$0.00
$0.00
$0.00
N/AN/AN/A156,525 shs
Diadexus, Inc.  stock logo
DDXS
Diadexus
$0.00
$0.01
$5.40
$53KN/A15,481 shs30 shs
Genfit S.A. stock logo
GNFT
Genfit
$3.45
-1.1%
$3.59
$2.89
$4.75
$171.93M1.0814,880 shs12,609 shs
PREV
PreveCeutical Medical
$0.00
$0.00
$0.00
N/AN/AN/A694,224 shs
TNGN
Tengion
$0.00
$0.00
$0.00
N/AN/A6,051 shs10,000 shs
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Canada House Wellness Group Inc stock logo
CHV
Canada House Wellness Group
0.00%0.00%0.00%0.00%0.00%
Diadexus, Inc.  stock logo
DDXS
Diadexus
0.00%0.00%0.00%0.00%0.00%
Genfit S.A. stock logo
GNFT
Genfit
+0.44%-0.43%-5.36%-11.21%-7.89%
PREV
PreveCeutical Medical
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Canada House Wellness Group Inc stock logo
CHV
Canada House Wellness Group
N/AN/AN/AN/AN/AN/AN/AN/A
Diadexus, Inc.  stock logo
DDXS
Diadexus
N/AN/AN/AN/AN/AN/AN/AN/A
Genfit S.A. stock logo
GNFT
Genfit
0.6838 of 5 stars
3.52.00.00.00.60.00.0
PREV
PreveCeutical Medical
N/AN/AN/AN/AN/AN/AN/AN/A
TNGN
Tengion
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Canada House Wellness Group Inc stock logo
CHV
Canada House Wellness Group
N/AN/AN/AN/A
Diadexus, Inc.  stock logo
DDXS
Diadexus
N/AN/AN/AN/A
Genfit S.A. stock logo
GNFT
Genfit
3.00
Buy$11.00218.84% Upside
PREV
PreveCeutical Medical
N/AN/AN/AN/A
TNGN
Tengion
N/AN/AN/AN/A

Current Analyst Ratings

Latest GNFT, CHV, DDXS, PREV, and TNGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/5/2024
Genfit S.A. stock logo
GNFT
Genfit
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Canada House Wellness Group Inc stock logo
CHV
Canada House Wellness Group
N/AN/AN/AN/AN/AN/A
Diadexus, Inc.  stock logo
DDXS
Diadexus
N/AN/AN/AN/AN/AN/A
Genfit S.A. stock logo
GNFT
Genfit
$28.57M6.02N/AN/A$1.48 per share2.33
PREV
PreveCeutical Medical
N/AN/AN/AN/AN/AN/A
TNGN
Tengion
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Canada House Wellness Group Inc stock logo
CHV
Canada House Wellness Group
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Diadexus, Inc.  stock logo
DDXS
Diadexus
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Genfit S.A. stock logo
GNFT
Genfit
-$31.27MN/A0.00N/AN/AN/AN/AN/A7/4/2024 (Estimated)
PREV
PreveCeutical Medical
N/AN/A0.00N/AN/AN/AN/AN/AN/A
TNGN
Tengion
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Canada House Wellness Group Inc stock logo
CHV
Canada House Wellness Group
N/AN/AN/AN/AN/A
Diadexus, Inc.  stock logo
DDXS
Diadexus
N/AN/AN/AN/AN/A
Genfit S.A. stock logo
GNFT
Genfit
N/AN/AN/AN/AN/A
PREV
PreveCeutical Medical
N/AN/AN/AN/AN/A
TNGN
Tengion
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Canada House Wellness Group Inc stock logo
CHV
Canada House Wellness Group
N/AN/AN/A
Diadexus, Inc.  stock logo
DDXS
Diadexus
N/AN/AN/A
Genfit S.A. stock logo
GNFT
Genfit
0.92
2.94
2.94
PREV
PreveCeutical Medical
N/AN/AN/A
TNGN
Tengion
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Canada House Wellness Group Inc stock logo
CHV
Canada House Wellness Group
N/A
Diadexus, Inc.  stock logo
DDXS
Diadexus
N/A
Genfit S.A. stock logo
GNFT
Genfit
2.24%
PREV
PreveCeutical Medical
N/A
TNGN
Tengion
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Canada House Wellness Group Inc stock logo
CHV
Canada House Wellness Group
N/AN/AN/ANot Optionable
Diadexus, Inc.  stock logo
DDXS
Diadexus
N/A4.10 millionN/ANot Optionable
Genfit S.A. stock logo
GNFT
Genfit
15949.84 million47.74 millionNot Optionable
PREV
PreveCeutical Medical
N/AN/AN/ANot Optionable
TNGN
Tengion
147,000N/AN/ANot Optionable

GNFT, CHV, DDXS, PREV, and TNGN Headlines

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Canada House Wellness Group logo

Canada House Wellness Group

CNSX:CHV
Canada House Cannabis Group Inc., through its subsidiaries, provides medical grade cannabis products in Canada. The company offers cannabinoid therapy products and services to patients, as well as owns and operates medicinal cannabis clinics. It also provides a cloud-based software that links physicians, providers, and patients to data that supports treatment with medical cannabis. The company serves its products under the Abba Medix, ICM Air, ICM Fogo, H-Series, Fleurs de chez nous, and Vandoos brand names. Canada House Cannabis Group Inc. is headquartered in Pickering, Canada.
Diadexus logo

Diadexus

OTCMKTS:DDXS
Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA.
Genfit logo

Genfit

NASDAQ:GNFT
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

PreveCeutical Medical

CNSX:PREV
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; BSV Peptide Program for targeting cancer progression; Non-Addictive Analgesic for pain management; and Dual Gene Therapy for type 2 diabetes and obesity. The company also develops a range of medicinal cannabis-based products. PreveCeutical Medical Inc. is headquartered in Vancouver, Canada.

Tengion

OTCMKTS:TNGN
Tengion, Inc. is a medicine company, focuses on discovering, developing, manufacturing and commercializing of neo-organs and products. The company was founded by Steven Nichtberger and David I. Scheer on July 10, 2003 and is headquartered in Winston-Salem, NC.